Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH (Reuters) – Combining Roche’s Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *